Ovarian cancer is a malignant neoplasm arising from ovarian tissue, most commonly epithelial origin, and often presents at advanced stage because early symptoms are nonspecific.
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
A randomized trial shows self-acupressure reduces fatigue and improves quality of life in ovarian cancer; a systematic review finds light to moderate massage safe for cancer patients.
Dosing has begun in a Phase 1 trial of ZI-MA4-1, the first MAGE-A4-targeting TCR-NK cell therapy for solid tumours, with initial data expected from mid-2026. The off-the-shelf therapy is being evaluated at two UK sites.
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
A study in Cancer Cell reveals that immature NK cells in donor cord blood can sabotage CAR NK cell therapy through trogocytosis, causing fratricide. Removing these cells before manufacturing improves antitumor activity in preclinical models, offering a strategy for more consistent off-the-shelf therapies.
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
In Australia, 19 women are diagnosed daily with gynaecological cancer, and experts say late detection is the primary issue. Ovarian cancer is often caught at advanced stages, while endometrial cancer deaths are rising. Personal stories underscore the need for early symptom awareness.
Allarity Therapeutics will present a Trial-in-Progress poster at the ESMO Gynaecological Cancers Congress 2026 on its Phase 2 ovarian cancer trial of stenoparib. The company also dosed first patients in February 2026 in a VA-funded Phase 2 trial of stenoparib plus temozolomide for relapsed small cell lung cancer.
A breakthrough ovarian cancer drug, mirvetuximab soravtansine, is now available on the NHS, offering extended survival and improved quality of life. The 'biological missile' therapy targets cancer cells directly, reducing side-effects compared to standard chemotherapy. Up to 400 patients in England could benefit each year.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779538 |
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07778498 |
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07776691 |
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07776171 |
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07761416 |
Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07760012 |
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors |
RECRUITING | NA |
| NCT07757711 |
Implementation of New Models of Ovarian Carcinoma Resistant to Therapy |
NOT_YET_RECRUITING | |
| NCT07755436 |
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. |
RECRUITING | PHASE1 |
| NCT07752875 |
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07747506 |
Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) |
NOT_YET_RECRUITING | PHASE2 |
